Clinical trial NCT03431311: T Cell Receptor Based Therapy of Metastatic Colorectal Cancer
Official title: Protocol for Treatment Under Hospital Exemption: T Cell Receptor Based Therapy of Metastatic Colorectal Cancer With mRNA-engineered T Cells Targeting Transforming Growth Factor Beta Receptor Type II (TGFβII)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Colorectal Cancer
Keywords: MSI
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2018-02-13
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: T Cell Receptor Based Therapy of Metastatic Colorectal Cancer With mRNA-engineered T Cells Targeting Transforming Growth Factor Beta Receptor Type II (TGFβII)

Detailed description: Patients with advanced metastatic colorectal cancer who have no other effective treatment options will be offered the treatment. These patients have a poor prognosis, and there is a strong need for improved therapy.

The patients will be given adoptive cell therapy (ACT) with Radium-1 TCR+ T cells transiently redirected against the TGFβRII frameshift antigen which is expressed in MSI+ colon cancer. The first report on TCR therapy in colon cancer was targeting carcinoembryonic antigen (CEA) where some evidence of clinical response was seen, but the T-cell function may have been inhibited due to the necessity to resolve the severe colitis which occurred due to the presence of CEA in normal cells in the colon. This demonstrates the feasibility of T-cell therapy in metastatic colon cancer, but also the limitations of targeting CEA as an antigen.

Eligibility criteria: Inclusion Criteria:

* Patients with metastatic colon cancer which is MSI+ with the presence of the -1A deletion in TGFβRII gene, and positive for HLA-A02 genotype
* Measurable disease
* Female or male patients. Fertile females must have a negative pregnancy test before inclusion in the trial. Both fertile men and women must be ready and able to use highly effective methods of contraception, defined as use of oral, implanted, injectable, and mechanical or barrier products for the prevention of pregnancy during participation of the trial
* Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1
* Age 18 years and older
* Life expectancy of at least 3 months
* Signed informed consent (by the subject or subject's legal representative) obtained before any trial-related procedures.
* Adequate organ function, measured by pre-defined laboratory values

Exclusion criteria

* Other metastatic malignancies
* Any other anti-tumour treatment within 4 weeks prior to first administration of cells.
* Steroid treatment, except substitution dose
* Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina or serious cardiac arrhythmia
* Active infection requiring antibiotic therapy
* Pregnancy or lactation
* Known hypersensitivity to any of the components of the investigational product
* Patients who test positive for hepatitis B, C, HIV or syphilis
* Any reason why, in the opinion of the investigator, the patient should not participate

Primary outcomes:
measure: Incidence, nature, and severity of adverse events graded according to NCI CTCAE v4.0
timeFrame: 2 years
Secondary outcomes:
measure: Progression free survival (PFS)
timeFrame: 2 years
measure: Radiological response rate (ORR)
timeFrame: 2 years
measure: Overall survival (OS)
timeFrame: 2 years
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital
Study officials:
affiliation: Oslo University Hospital
name: Svein Dueland, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: